Search results
Added:
1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further…
View more
Added:
7 months ago
EHRA 2025 - Positive safety results of the Affera mapping and ablation system for the treatment of ventricular arrhythmias (VA) show a 6% rate of major complication.Dr Frédéric Sacher (IHU Liryc, Bordeaux, FR) joins us on-site at EHRA Congress 2025 to discuss safety results from the European Affera Ventricular Arrhythmia Ablation Registry, investigating VA ablation with the Affera Sphere-9…
View more
Added:
11 months ago
AHA Conference 2024 - BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).BROOKLYN is a phase 3,…
View more
Added:
2 years ago
A single centre, prospective, non-randomised study from DrDaniela Trabattoni (Monzino Cardiology Centre,Milan, IT) following device implantation of the Occlutech PFO Closure device in 442 consecutive patients.The study is particularly interesting due to the scarcity of data available on the long term follow up (over 5 years after) of device implantation. Also, the results are focussed not only…
View more
Added:
12 months ago
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone.Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).REALIZE-K is a phase 4…
View more
Added:
3 weeks ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Added:
1 week ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with…
View more
Added:
3 weeks ago
TCT 2025 - Sub-anlysis findings showed positive safety and efficacy outcomes of the PASCAL Precision system in degenerative mitral regurgitation (DMR) patients.Dr P Kasi Ramanathan (Promedica Toledo Hospital, US) joins us on-site at TCT 2025 to share the findings from a sub-analysis looking at the affect of implant location and leaflet lesion location on the safety and effectiveness of the PASCAL…
View more
Added:
2 weeks ago
TCT 2025 – Dr Nadira Hamid (Minneapolis Heart Institute, US), interventional echocardiographer sits down with ENCIRCLE's (Edwards Lifesciences) Principal Investigator, Dr David V Daniels (California Pacific Medical Center, US) to have a deep dive into the latest data with SAPIEN M3.The ENCIRCLE trial (NCT04153292) is a prospective, multicentre, single-arm study evaluating the safety and…
View more